The honest answer is that the research contradicts itself — and understanding why is more useful than a false yes or no. One set of studies suggests GLP-1 drugs like Ozempic, Wegovy, and Mounjaro lower the risk of autoimmune disease and improve conditions like psoriasis and rheumatoid arthritis. Another set suggests they raise the risk of some autoimmune conditions. Both are real, published findings. The truth lives in the gap between them, and here is the most important thing to know up front: there is no GLP-1 drug approved for any autoimmune disease. This is an active area of research, not an available treatment.
Here is why the question is legitimate rather than hype: GLP-1 receptors sit on immune cells, and these drugs measurably calm several of the same inflammatory pathways that expensive biologic autoimmune drugs target. The biology is promising. The human outcomes just don’t agree yet.
About this video: the on-screen presenter and voice are AI-generated. The script and all medical content were written and reviewed by Natalie Howard, DNP, MBA, FNP-C, board-certified family nurse practitioner, and every clinical claim is tied to the published research cited below.
Why would a weight-loss drug affect the immune system?
Because GLP-1 drugs do more than lower blood sugar. They dampen a specific set of inflammatory signals — NF-κB, IL-6, TNF-α, and the IL-17/IL-23 axis. If those names look familiar, it’s because they are the exact targets of the biologic medications already used to treat autoimmune conditions like psoriasis and rheumatoid arthritis.
In small studies, GLP-1 drugs have been associated with improvement in psoriasis and psoriatic arthritis severity. Semaglutide has been linked to better joint outcomes in rheumatoid arthritis. And a large multi-center study found that people taking GLP-1 drugs were less likely to develop immune-mediated inflammatory disease in the first place. On its own, that looks like the start of a breakthrough.
So why do other studies show the opposite?
Because a separate large real-world study found that people on GLP-1 drugs had higher rates of several autoimmune conditions — including psoriasis, rheumatoid arthritis, and autoimmune thyroid disease — compared with people on an older diabetes drug (a DPP-4 inhibitor). Even at the same 2025 rheumatology conference, one large analysis linked GLP-1 drugs to a lower risk of developing immune-mediated inflammatory disease, while another found a higher flare burden in rheumatoid arthritis patients who added a GLP-1 drug to their standard treatment.
Here is the detail that unlocks the contradiction: the result depends heavily on what the GLP-1 drug is compared to. Against DPP-4 inhibitors, GLP-1 users showed higher autoimmune rates. Against a different class (SGLT2 inhibitors), there was no significant difference. When an apparent “effect” shifts based on the comparison group, that is a strong signal that we are not looking at a clean, direct effect of the drug itself. We are looking at something more tangled.
What’s the honest synthesis?
The most defensible read is that the benefit, where it is real, is largely indirect.
Obesity and insulin resistance are themselves inflammatory states — they actively worsen immune dysregulation and can drive autoimmune flares. So when someone on a GLP-1 drug improves, it is often impossible to separate two explanations: did the drug directly calm their immune system, or did losing weight and improving their metabolic health lower the inflammation that was fueling their disease? Current reviews suggest a substantial part of the benefit runs through the weight and metabolic improvement, rather than through the drug reprogramming immune function.
That is still a meaningful benefit. It is simply not the science-fiction version where a weight-loss drug becomes an autoimmune cure. And it does not change the bottom line: no GLP-1 is approved for any autoimmune indication, and the direct immunomodulatory effect remains unproven.
What does this mean if you have an autoimmune condition?
It means your metabolic health and your immune health are genuinely connected — and that connection is worth taking seriously, with your own care team.
If you live with an autoimmune condition and also carry excess weight or insulin resistance, addressing the metabolic side is a reasonable part of the overall picture, because the inflammation link is real. What the evidence does not support is seeking a GLP-1 drug specifically to treat an autoimmune disease. That decision, and any GLP-1 prescription, belongs with your clinician and your rheumatologist or specialist — not with a headline.
A useful first step is understanding your own metabolic markers. Ask your provider about:
- Fasting insulin
- A1C
- HOMA-IR
- hs-CRP (a general inflammation marker)
Want to go deeper? Our free guide covers the 5 metabolic labs every GLP-1 patient should be tracking — including fasting insulin and HOMA-IR — with reference ranges and the exact language to request them. Get the free lab guide here.
Work with Moxie Wellness
At Moxie Wellness, we practice metabolic medicine — evaluating and treating the insulin resistance and inflammation that intersect with so many chronic conditions. If you want a clinician who reads the research honestly, including where it’s still unsettled, and who looks at your metabolic health alongside the rest of your care, we can help. Moxie is a cash-pay telehealth practice, currently licensed in Florida and Washington, DC. We do not replace your rheumatologist or specialist — we work alongside them.
Visit Moxie Wellness to book a consultation.
Natalie Howard, DNP, MBA, FNP-C — board-certified family nurse practitioner, founder of Moxie Wellness.
Frequently asked questions
Can Ozempic or Wegovy treat autoimmune disease?
No GLP-1 drug is approved to treat any autoimmune disease. Some studies show associated improvement in conditions like psoriasis and rheumatoid arthritis, but the evidence is mixed and the benefit appears to be largely indirect — through weight loss and reduced metabolic inflammation rather than direct immune treatment.
Are GLP-1 drugs anti-inflammatory?
They do reduce several inflammatory signals (NF-κB, IL-6, TNF-α, IL-17/23) in laboratory and early clinical studies. Whether that translates into meaningful treatment of autoimmune disease in people is not yet established, and some studies have found higher rates of certain autoimmune conditions among GLP-1 users.
Do GLP-1 drugs cause autoimmune disease?
The data is genuinely mixed. One large study found higher rates of some autoimmune conditions among GLP-1 users versus one comparison drug, but no difference versus another. This inconsistency suggests the association is not a clean, direct cause-and-effect and requires more research.
Should I ask my doctor for a GLP-1 for my autoimmune condition?
This is a conversation for you, your primary provider, and your specialist — not something to pursue based on early or conflicting research. There is no approved autoimmune indication. If you also have obesity or insulin resistance, the metabolic conversation is worth having on its own merits.
What is the connection between metabolic health and autoimmune disease?
Obesity and insulin resistance are inflammatory states that can worsen immune dysregulation and autoimmune flares. Improving metabolic health can lower systemic inflammation, which is likely a large part of any benefit seen with GLP-1 drugs in autoimmune conditions.
References
- Association of semaglutide prescription with improved joint outcomes in rheumatoid arthritis patients. ACR Convergence 2025, Abstract #2107645. acrabstracts.org
- Risk of immune-mediated inflammatory diseases and other safety outcomes in patients with T2DM and obesity initiating GLP-1 RA: a propensity score-matched multi-center study using the TriNetX global network. ACR Convergence 2025, Abstract #2128560. acrabstracts.org
- Impact of SGLT2 inhibitors and GLP-1 agonists on RA flares in patients on DMARD therapy: a retrospective study. ACR Convergence 2025, Abstract #2128553. acrabstracts.org
- Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: a real-world evidence study. PubMed 40544585. PubMed
- The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. PMC12634801. PMC
- GLP-1RAs in psoriasis and psoriatic arthritis. Frontiers in Immunology, 2026. PMC13161150. PMC
- Glucagon-like peptide-1 (GLP-1) receptor agonists in rheumatology: a review of current evidence and future directions. PubMed 40617296. PubMed
This article is educational and is not a substitute for individualized medical advice. Consult your own clinician about your situation.